| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/05/2001 | CA2384662A1 41 human secreted proteins |
| 04/05/2001 | CA2384659A1 37 human secreted proteins |
| 04/05/2001 | CA2384265A1 Benzodiazepin derivatives, the production and use thereof |
| 04/05/2001 | CA2382892A1 Substituted benzimidazol derivatives, processes for preparing them and their use as pharmaceutical compositions |
| 04/05/2001 | CA2352194A1 Azepinoindole derivatives, the production and use thereof |
| 04/04/2001 | EP1088824A2 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors |
| 04/04/2001 | EP1088822A1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 04/04/2001 | EP1088821A1 Pharmaceutically active sulfonamide derivatives |
| 04/04/2001 | EP1088819A2 6-azauracil derivatives as thyroid receptor ligands |
| 04/04/2001 | EP1088815A1 Pharmaceutically active sulfonyl amino acid derivatives |
| 04/04/2001 | EP1088554A1 Controlled release drug association containing 5-isosorbide mononitrate and acetylsalicylic acid |
| 04/04/2001 | EP1088062A1 Transplants for myocardial scars |
| 04/04/2001 | EP1087981A2 Prenyl transferase inhibitors |
| 04/04/2001 | EP1087973A1 Imidazotriazolopyrimidines used as a drug having an adenosine antagonist activity |
| 04/04/2001 | EP1087964A1 N-benzodioxanylmethyl-1-piperidyl-methylamine compounds having affinity for 5-ht receptors |
| 04/04/2001 | EP1087963A1 Inhibitors of glycogen synthase kinase 3 |
| 04/04/2001 | EP1087953A1 Nitrate salts of antihypertensive medicines |
| 04/04/2001 | EP1087946A1 Aryl alkanoylpyridazines |
| 04/04/2001 | EP1087943A1 Therapeutic biaryl derivatives |
| 04/04/2001 | EP1087937A1 Cyclic hydroxamic acids as metalloproteinase inhibitors |
| 04/04/2001 | EP1087934A1 Aminocyclohexyl ether compounds and uses thereof |
| 04/04/2001 | EP1087801A1 Topoisomerase inhibitors for prevention of restenosis |
| 04/04/2001 | EP1087785A2 Combination of radiotherapy and anti-angiogenic factors |
| 04/04/2001 | EP1087781A1 Dietary supplement for supporting cerebrovascular tone |
| 04/04/2001 | EP1087775A1 Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination |
| 04/04/2001 | EP1087769A1 Use of a pyridazinone derative |
| 04/04/2001 | EP1087762A1 Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects |
| 04/04/2001 | EP1087761A2 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
| 04/04/2001 | EP1087661A1 Il-8 receptor antagonists |
| 04/04/2001 | EP0929216A4 Method of treating post menopausal diseases, including osteoporosis |
| 04/04/2001 | EP0824515B1 Substituted phenyl amidines, medicaments containing these compounds and process for producing them |
| 04/04/2001 | EP0636127B1 Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity |
| 04/04/2001 | EP0620732B1 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| 04/04/2001 | CN1290349A Pharmaceutical grade ginkgo biloba |
| 04/04/2001 | CN1290266A Benzofuran-4-carboxamides and their therapeutical use |
| 04/04/2001 | CN1290265A Thrombin receptor antagonists |
| 04/04/2001 | CN1290260A Hydroxamic and carboxylic acid derivatives |
| 04/04/2001 | CN1290258A Arylpiperazines having activity at the serotnin 1A receptor |
| 04/04/2001 | CN1290255A Dihydroxyhexanoic acid derivatives |
| 04/04/2001 | CN1290250A Sulfonylamino derivatives which inhibit matrix-degrading metallopr teinases |
| 04/04/2001 | CN1290167A Dried or frozen pharmaceutical prepartion containing class III antiarrhythmic compound |
| 04/04/2001 | CN1290165A Benzothiazole Protein tyrosine kinase inhibitors |
| 04/04/2001 | CN1289615A Medical capsule for elongating life and its preparing process |
| 04/04/2001 | CN1064041C Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use for production of pharmaceutical preparations, and pharmaceutical preparations containing them |
| 04/04/2001 | CN1063963C Method for preparing medicinal spirit containing maple-lotus-cassia against apoplexy |
| 04/04/2001 | CN1063950C Brain reinforcing ointment |
| 04/04/2001 | CN1063942C Use of thiazolidine derivative for making medicaments |
| 04/03/2001 | US6211393 Radicals linked to si are si--o--c, si--s--c or si--n--c type bonds and are hydrolyzable in vivo, forming si--oh bonds that are biologically active especially when in contact with living tissue |
| 04/03/2001 | US6211368 Hydrolysis of corresponding ester |
| 04/03/2001 | US6211362 Pyrroloazepine compounds |
| 04/03/2001 | US6211247 Administration of resveratrol to prevent or treat restenosis following coronary intervention |
| 04/03/2001 | US6211242 Benzamide derivatives as vasopressin antagonists |
| 04/03/2001 | US6211234 Substituted phenyl compounds |
| 04/03/2001 | US6211233 Prostaglandin pharmaceutical compositions |
| 04/03/2001 | US6211208 2-aminopyridines containing fused ring substituents |
| 04/03/2001 | US6211186 Polyoxyalkylene glycol modified with n-heterocycle derivative with amidine or guanidine group; diaper rash, obesity, acne, periodontal disease, contraceptives; protease and lipase inhibitors |
| 04/03/2001 | US6211182 Histamine h3-antagonists; antiinflammatory agents, antiallergens, antiasthmatics; nervous system, psychological, sleep, and gastrointestinal disorders |
| 04/03/2001 | US6211179 Treating sexual disorders, impotency, and menopause; administering purine derivative; nitric oxide synthase substrates |
| 04/03/2001 | US6211175 Cardiac diseases improving method |
| 04/03/2001 | US6211167 Arylsulfonanilide phosphates |
| 04/03/2001 | US6211157 Administering bone-derived protein; ultrafiltration, ion exchanging, liquid chromatography |
| 04/03/2001 | US6211151 Peptides with organo-protective activity, a process for preparation thereof and their use in therapy |
| 04/03/2001 | US6211147 Method of promoting angiogenesis using relaxin |
| 04/03/2001 | US6210913 Modulation of integrin-mediated signal transduction |
| 04/03/2001 | US6210670 Cross-reacting monoclonal antibodies specific for E-selectin and P-selectin |
| 04/03/2001 | CA2188147C Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| 04/03/2001 | CA2034811C Selective processes for fosinopril polymorphs |
| 04/01/2001 | CA2321324A1 Quinolin-4yl derivatives |
| 03/30/2001 | WO2003044525A1 Targeting cells having mad2 mutation for treatment and/or prevention of disease |
| 03/30/2001 | WO2003042411A2 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease |
| 03/30/2001 | CA2321379A1 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors |
| 03/29/2001 | WO2001021831A1 Method for identifying novel genes involved in the regulation of angiogenesis, study of said genes and use thereof for therapeutic purposes |
| 03/29/2001 | WO2001021812A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | WO2001021789A1 Ribozymes used for restenosis prevention |
| 03/29/2001 | WO2001021773A2 Human endothelin converting enzyme-like proteins and polynucleotides encoding the same |
| 03/29/2001 | WO2001021761A2 Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars |
| 03/29/2001 | WO2001021660A1 Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (dcm) |
| 03/29/2001 | WO2001021658A1 32 human secreted proteins |
| 03/29/2001 | WO2001021648A1 Uses of kappa-conotoxin pviia |
| 03/29/2001 | WO2001021628A1 A substantially cell membrane impermeable compound and use thereof |
| 03/29/2001 | WO2001021621A1 BENZO-FUSED DITHIEPINO[6,5-b]PYRIDINES, AND RELATED COMPOSITIONS AND METHODS |
| 03/29/2001 | WO2001021620A2 Amine derivatives of benzo-4,5-thieno-2,3-d pyrimidines |
| 03/29/2001 | WO2001021619A1 N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent |
| 03/29/2001 | WO2001021614A1 5-aminoalkyl and 5-aminocarbonyl substituted indoles |
| 03/29/2001 | WO2001021610A1 Benzopyran derivative |
| 03/29/2001 | WO2001021609A1 4-oxybenzopyran derivative |
| 03/29/2001 | WO2001021604A1 Substituted piperazine derivatives, the production thereof and their use as inhibitors of the microsomal triglyceride-transfer protein (mtp) |
| 03/29/2001 | WO2001021602A1 Oxa- and thiazole derivatives useful as antidiabetic and antiobesity agents |
| 03/29/2001 | WO2001021600A1 Caspase inhibitor |
| 03/29/2001 | WO2001021598A1 Therapeutic quinazoline compounds |
| 03/29/2001 | WO2001021591A1 Pyrazole derivatives |
| 03/29/2001 | WO2001021582A1 Biphenyl derivatives used as nhe-3 inhibitors |
| 03/29/2001 | WO2001021575A1 Anti-inflammatory nitro- and thia- fatty acids |
| 03/29/2001 | WO2001021574A1 Systems and methods for opening obstructed biological conduits |
| 03/29/2001 | WO2001021259A2 Use and compositions for treating platelet-related disorders using anagrelide |
| 03/29/2001 | WO2001021218A2 Method for determining viability of a myocardial segment |
| 03/29/2001 | WO2001021214A1 Gene therapy for cerebrovascular disorders |
| 03/29/2001 | WO2001021206A1 PREVENTIVES OR REMEDIES FOR MYOCARDITIS, DILATED CARDIOMYOPATHY AND CARDIAC INSUFFICIENCY CONTAINING NF-λB INHIBITORS AS THE ACTIVE INGREDIENT |
| 03/29/2001 | WO2001021205A1 Coupling factor 6 inhibitor and potentiator and use thereof |
| 03/29/2001 | WO2001021204A1 Therapeutic uses of m3 polypeptide |